TITLE

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy

AUTHOR(S)
Stankov, M V; El Khatib, M; Kumar Thakur, B; Heitmann, K; Panayotova-Dimitrova, D; Schoening, J; Bourquin, J P; Schweitzer, N; Leverkus, M; Welte, K; Reinhardt, D; Li, Z; Orkin, S H; Behrens, G M N; Klusmann, J H
PUB. DATE
March 2014
SOURCE
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p577
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Histone deacetylase (HDAC) inhibitors (HDACis) are well-characterized anti-cancer agents with promising results in clinical trials. However, mechanistically little is known regarding their selectivity in killing malignant cells while sparing normal cells. Gene expression-based chemical genomics identified HDACis as being particularly potent against Down syndrome-associated myeloid leukemia (DS-AMKL) blasts. Investigating the antileukemic function of HDACis revealed their transcriptional and post-translational regulation of key autophagic proteins, including ATG7. This leads to suppression of autophagy, a lysosomal degradation process that can protect cells against damaged or unnecessary organelles and protein aggregates. DS-AMKL cells exhibit low baseline autophagy due to mammalian target of rapamycin (mTOR) activation. Consequently, HDAC inhibition repressed autophagy below a critical threshold, which resulted in accumulation of mitochondria, production of reactive oxygen species, DNA damage and apoptosis. Those HDACi-mediated effects could be reverted upon autophagy activation or aggravated upon further pharmacological or genetic inhibition. Our findings were further extended to other major acute myeloid leukemia subgroups with low basal level autophagy. The constitutive suppression of autophagy due to mTOR activation represents an inherent difference between cancer and normal cells. Thus, via autophagy suppression, HDACis deprive cells of an essential pro-survival mechanism, which translates into an attractive strategy to specifically target cancer cells.
ACCESSION #
94762967

 

Related Articles

  • Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells. Petruccelli, Luca A.; Dupéré-Richer, Daphné; Pettersson, Filippa; Retrouvey, Hélène; Skoulikas, Sophia; Miller Jr., Wilson H. // PLoS ONE;2011, Vol. 6 Issue 6, p1 

    Histone deacetylase inhibitors (HDACi) are promising anti-cancer agents, however, their mechanisms of action remain unclear. In acute myeloid leukemia (AML) cells, HDACi have been reported to arrest growth and induce apoptosis. In this study, we elucidate details of the DNA damage induced by the...

  • Mitochondrial Apoptosis and FAK Signaling Disruption by a Novel Histone Deacetylase Inhibitor, HTPB, in Antitumor and Antimetastatic Mouse Models. Jiunn-Min Shieh; Tzu-Tang Wei; Yen-An Tang; Sin-Ming Huang; Wei-Ling Wen; Mei-Yu Chen; Hung-Chi Cheng; Santosh B. Salunke; Ching-Shih Chen; Pinpin Lin; Chien-Tien Chen; Yi-Ching Wang // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Background: Compound targeting histone deacetylase (HDAC) represents a new era in molecular cancer therapeutics. However, effective HDAC inhibitors for the treatment of solid tumors remain to be developed. Methodology/Principal Findings: Here, we propose a novel HDAC inhibitor,...

  • Mitochondrial Apoptosis and FAK Signaling Disruption by a Novel Histone Deacetylase Inhibitor, HTPB, in Antitumor and Antimetastatic Mouse Models. Jiunn-Min Shieh; Tzu-Tang Wei; Yen-An Tang; Sin-Ming Huang; Wei-Ling Wen; Mei-Yu Chen; Hung-Chi Cheng; Santosh B. Salunke; Ching-Shih Chen; Pinpin Lin; Chien-Tien Chen; Yi-Ching Wang // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Background: Compound targeting histone deacetylase (HDAC) represents a new era in molecular cancer therapeutics. However, effective HDAC inhibitors for the treatment of solid tumors remain to be developed. Methodology/Principal Findings: Here, we propose a novel HDAC inhibitor,...

  • MicroRNAs Contribute to Promyelocyte Apoptosis in As2O3-Treated APL Cells. Liang, Haihai; Li, Xuelian; Wang, Lu; Yu, Shaonan; Xu, Zhidan; Gu, Yunyan; Pan, Zhenwei; Li, Tianyu; Hu, Meiyu; Cui, Hairong; Liu, Xue; Zhang, Ying; Xu, Chaoqian; Guo, Rui; Lu, Yanjie; Yang, Baofeng; Shan, Hongli // Cellular Physiology & Biochemistry (Karger AG);Dec2013, Vol. 32 Issue 6, p1818 

    Background: Arsenic trioxide (As2O3), an ancient drug used in traditional Chinese medicine, has substantial anticancer activities, especially in the treatment of patients suffering from acute promyelocytic leukemia (APL); however the underlying mechanisms are not well understood. Methods: MTT...

  • Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer. Lin, Wen-Hsing; Yeh, Teng-Kuang; Jiaang, Weir-Torn; Yen, Kuei-Jung; Chen, Chun-Hwa; Huang, Chin-Ting; Yen, Shih-Chieh; Hsieh, Shu-Yi; Chou, Ling-Hui; Chen, Ching-Ping; Chiu, Chun-Hsien; Kao, Li-Chun; Chao, Yu-Sheng; Chen, Chiung-Tong; Hsu, John T.-A. // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Overexpression or/and activating mutation of FLT3 kinase play a major driving role in the pathogenesis of acute myeloid leukemia (AML). Hence, pharmacologic inhibitors of FLT3 are of therapeutic potential for AML treatment. In this study, BPR1J-340 was identified as a novel potent FLT3 inhibitor...

  • Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Schwartsmann, G.; Fernandes, M. S.; Schaan, M. D.; Moschen, M.; Gerhardt, L. M.; di Leone, L.; Loitzembauer, B.; Kalakun, L. // Leukemia (08876924);Mar97 Supplement 1, Vol. 11, pS28 

    The authors report on the preliminary results of an ongoing phase II trial whereby the combination of the new DNA hypome-thylating agent, 5-Aza-deoxycytidine (DAC), plus daunorubicin was given as first-line induction therapy to non-pretreated patients with acute myeloid leukemia (except FAB M3)....

  • Drug May Benefit Older Leukemia Patients.  // Journal of Gerontological Nursing;Mar2010, Vol. 36 Issue 3, p6 

    The author discusses findings that suggest that the drug decitabine could benefit older patients with acute myeloid leukemia (AML). The article notes that approximately two-thirds of older patients with AML do not receive treatment since the therapy is often ineffective and is risky. Decitabine...

  • The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. Min-Wu Chao; Mei-Jung Lai; Jing-Ping Liou; Ya-Ling Chang; Jing-Chi Wang; Shiow-Lin Pan; Che-Ming Teng // Journal of Hematology & Oncology;Jul2015, Vol. 8 Issue 1, p1 

    Background: Combination therapy is a key strategy for minimizing drug resistance, a common problem in cancer therapy. The microtubule-depolymerizing agent vincristine is widely used in the treatment of acute leukemia. In order to decrease toxicity and chemoresistance of vincristine, this study...

  • Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. DeAngelo, D J; Spencer, A; Bhalla, K N; Prince, H M; Fischer, T; Kindler, T; Giles, F J; Scott, J W; Parker, K; Liu, A; Woo, M; Atadja, P; Mishra, K K; Ottmann, O G // Leukemia (08876924);Aug2013, Vol. 27 Issue 8, p1628 

    Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell lines. A phase Ia/II study was designed to determine the maximum-tolerated dose (MTD) of daily panobinostat,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics